<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02305654</url>
  </required_header>
  <id_info>
    <org_study_id>ICR CTSU/2014/10048</org_study_id>
    <secondary_id>CRUK/13/005</secondary_id>
    <secondary_id>13580965</secondary_id>
    <secondary_id>EA8134</secondary_id>
    <secondary_id>IRCI004</secondary_id>
    <secondary_id>2015-001199-23</secondary_id>
    <nct_id>NCT02305654</nct_id>
  </id_info>
  <brief_title>International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)</brief_title>
  <acronym>InPACT</acronym>
  <official_title>International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Cancer Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>ECOG-ACRIN Cancer Research Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Cancer Trials Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute of Cancer Research, United Kingdom</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an international phase III trial, with a Bayesian design, incorporating two
      sequential randomisations. It efficiently examines a series of questions that routinely arise
      in the sequencing of treatment. The study design has evolved from lengthy international
      consultation that has enabled us to build consensus over which questions arise from current
      knowledge and practice. It will enable potential randomisation for the majority of patients
      with inguinal lymph node metastases and will provide data to inform future clinical
      decisions.

      InPACT-neoadjuvant patients are stratified by disease burden as assessed by radiological
      criteria. Treatment options are then defined according to the disease burden strata.
      Treatment is allocated by randomisation. Patients may be allocated to one of three initial
      treatments:

      A. standard surgery (ILND); B. neoadjuvant chemotherapy followed by standard surgery (ILND);
      or C. neoadjuvant chemoradiotherapy followed by standard surgery (ILND).

      After ILND, patients are defined as being at low or high risk of recurrence based on
      histological interpretation of the ILND specimen. Patients at high risk of relapse are
      eligible for InPACT-pelvis, where they are randomised to either:

      P. prophylactic PLND Q. no prophylactic PLND
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 12, 2017</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 5 years</time_frame>
    <description>The primary outcome measure that will be measured for all trial patients is survival time. This is defined in whole days as the time from the date of randomisation to the date of death from any cause; for those who have not been reported as dead at the time of analysis, the survival time will be censored at the date of last follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease specific survival time</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Disease-specific survival time which is defined in whole days as the time from the date of randomisation to the date of death specifically from disease; for those who have not been reported as dead at the time of analysis, the survival time will be censored at the date of last follow-up and for those whose death is reported as non-disease specific then the survival time will be censored at date of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients experience a grade 3 or 4 toxicity</measure>
    <time_frame>up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival time</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Disease-free survival time (DFST) which is defined in whole days as the time from date of randomisation to the date of either locoregional recurrence, distant metastasis or death from disease, whichever occurs first; for those who have not been reported as experiencing any of these events, the DFST will be censored at the date last known to be alive and free of disease or date of non-disease-specific death. A supplementary exploratory outcome measure will also be calculated taking date of penectomy as the origin rather than date of randomisation.
Subsidiary outcome measures will be
locoregional recurrence free survival time (LRFST).
distant metastases free survival time (DMFST).
A supplementary exploratory outcome measure will also be calculated taking date of penectomy as the origin for all these outcome measures rather than date of randomisation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of surgical complication</measure>
    <time_frame>up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Is it possible to achieve pathological nodal assessment after chemotherapy</measure>
    <time_frame>12 weeks</time_frame>
    <description>Feasibility of pathological nodal assessment after chemotherapy which is recorded as whether or not it was possible to achieve a pathological nodal assessment after chemotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Baseline, 3, 6, 9, 12, 18, 24 and 36 months</time_frame>
    <description>Measured using the EORTC-QLQC30 and Lymphodema-QL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Pathological complete remission</measure>
    <time_frame>Time to complete remission after randomisation</time_frame>
    <description>Measured for all patients in InPACT-neoadjuvant:
Absolute absence of disease on histological examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operability</measure>
    <time_frame>2-6 weeks</time_frame>
    <description>Measured for all trial patients in InPACT-neoadjuvant. Operability which will be recorded as whether or not the planned inguinal node dissection was undertaken and the reasons if it did not occur.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Lower limb/scrotal oedema</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Occurrence of Lower limb/scrotal oedema which is recorded as whether or not the patient experiences a lower limb or scrotal oedema</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>On-schedule delivery of neoadjuvant therapy</measure>
    <time_frame>After randomisation up to 12 weeks</time_frame>
    <description>Feasibility of on-schedule delivery of neoadjuvant therapy</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Acceptability of randomisation</measure>
    <time_frame>up to 5 years</time_frame>
    <description>In addition to the outcome measures, the acceptability of both randomisations will be monitored based on the proportion of eligible patients approached for randomisation, the proportion of approached patients consenting to randomisation and the proportion of randomised patients receiving their allocated treatment. This will provide ongoing information regarding the feasibility of the trial successfully completing to target.</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Squamous Cell Carcinoma of the Penis, Usual Type</condition>
  <arm_group>
    <arm_group_label>Arm A - Standard Surgery (ILND)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Part of randomisation 1.
The total treatment duration (Inguinal Lymph Node Dissection (ILND)) is estimated to be over 1 day for those patients allocated to Arm A - standard surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B - neoadjuvant chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part of randomisation 1.
Patients will receive up to 4 cycles of Paclitaxel, Ifosfamide, and Cisplatin (TIP).
Administration on an outpatient basis:
Paclitaxel 175 mg/m2, day 1, Ifosfamide 900 mg/m2, days 2-5, Cisplatin 15 mg/m2, days 1-5
Administration on an inpatient basis:
Paclitaxel 175 mg/m2, day 1, Ifosfamide 1200 mg/m2, days 1-3, Cisplatin 25 mg/m2, days 1-3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C - neoadjuvant chemoradiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part of randomisation 1.
Radiotherapy dose is 45Gy in 25 fractions over 5 weeks using 6-10 MV photons to all regions.
Concurrent cisplatin 40mg/m2 will be given weekly, subject to GFR&gt;45mls/min.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm P - prophylactic PLND</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part of randomisation 2.
Prophylactic pelvic lymph node dissection (PLND) - The total treatment duration is estimated to be over 1 day.
Patients who have NOT received neoadjuvant chemoradiotherapy will receive adjuvant chemoradiotherapy:
Cisplatin 40mg/m2 will be given weekly, subject to GFR&gt;45mls/min.
Groin: One or both groins may be boosted up to 54Gy in 25 fractions. An IMRT boost of up to 57 Gy can be given to recurrent or residual macroscopic tumour
Pelvis: the dose is limited to 45Gy unless IMRT is available. An IMRT boost of up to 54Gy in 25 fractions is applied to:
Any macroscopic tumour or pathological lymph nodes
Electively to external iliac nodes in patient with high disease burden
Patients who have had neoadjuvant chemoradiotherapy will have prophylactic PLND alone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm Q - Surveillance no prophylactic PLND</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no prophylactic PLND Part of randomisation 2.
For patients who have NOT received neoadjuvant chemoradiotherapy:
Groin: One or both groins may be boosted up to 54Gy in 25 fractions. An IMRT boost of up to 57 Gy can be given to recurrent or residual macroscopic tumour
Pelvis: the dose is limited to 45Gy unless IMRT is available. An IMRT boost of up to 54Gy in 25 fractions is applied to:
Any macroscopic tumour or pathological lymph nodes Electively to external iliac nodes in patient with high disease burden</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ILND - Inguinal Lymph Node Dissection</intervention_name>
    <description>Surgery to remove the lymph nodes in the groin near to where the cancer first appeared.</description>
    <arm_group_label>Arm A - Standard Surgery (ILND)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Dose 175mg/m2 as part of TIP regimen.</description>
    <arm_group_label>Arm B - neoadjuvant chemotherapy</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide</intervention_name>
    <description>Dose 900mg/m2 as part of TIP regimen.</description>
    <arm_group_label>Arm B - neoadjuvant chemotherapy</arm_group_label>
    <other_name>Mitoxana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Dose 15mg/m2 as part of TIP regimen (neoadjuvant chemotherapy arm) Dose 40mg/m2 for use concurrently with raditotherapy (chemoradiotherapy arm)</description>
    <arm_group_label>Arm B - neoadjuvant chemotherapy</arm_group_label>
    <arm_group_label>Arm C - neoadjuvant chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intensity modulated radiation treatment (IMRT)</intervention_name>
    <description>Treatment with very high energy X-rays (radiotherapy).</description>
    <arm_group_label>Arm C - neoadjuvant chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Prophylactic PLND - pelvic lymph node dissection</intervention_name>
    <description>Surgery to remove the lymph nodes deeper in the pelvis, further away from where the cancer first appeared, that are at high risk of harbouring cancer.</description>
    <arm_group_label>Arm P - prophylactic PLND</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent

          2. Measurable disease as determined by RECIST (version 1.1) criteria;

          3. Histologically-proven squamous cell carcinoma of the penis,

          4. Stage:

               -  any T, N1 (i.e. a palpable mobile unilateral inguinal lymph node), M0 or;

               -  any T, N2 (i.e. palpable mobile multiple or bilateral inguinal lymph nodes), M0
                  or;

               -  any T, N3 (i.e. fixed inguinal nodal mass or any pelvic lymphadenopathy), M0

          5. Performance Status ECOG 0, 1 or 2.

        Exclusion Criteria:

          1. Pure verrucous carcinoma of the penis,

          2. Nonsquamous malignancy of the penis,

          3. Squamous carcinoma of the urethra,

          4. Stage M1,

          5. Previous chemotherapy or chemoradiotherapy,

          6. Concurrent malignancy (other than SCC or Basal Cell Carcinoma of non-penile skin) that
             has required surgical or non-surgical treatment in the last 3 years.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steve Nicholson</last_name>
    <role>Study Chair</role>
    <affiliation>Southend University Hospital Foundation NHS Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Curtis Pettaway</last_name>
    <role>Study Chair</role>
    <affiliation>University of Texas M.D. Anderson Cancer Center ; 713-792-3250 ; cpettawa@mdanderson.org</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>UK - InPACT Senior Trial Manager</last_name>
    <phone>02087224261</phone>
    <email>InPACT-icrctsu@icr.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>US/Canada - InPACT DA for EA8134</last_name>
    <phone>(857)504-2900</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Los Angeles County-USC Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Schuckman</last_name>
      <phone>323-865-3700</phone>
      <email>anne.schuckman@med.usc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>USC / Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sia Daneshmand</last_name>
      <phone>323-865-3700</phone>
      <email>daneshma@usc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phil Spiess</last_name>
      <phone>813-745-8343</phone>
      <email>Philippe.spiess@moffitt.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Grady Health System</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital/Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Viraj Master</last_name>
      <phone>404-778-4898</phone>
      <email>vmaster@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lance Pagliaro</last_name>
      <email>pagliaro.lance@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Stephen Boorjian /Jeffrey Karnes (karnes.r@mayo.edu)</last_name>
      <phone>(507)284-4015 / (507)266-9968</phone>
      <email>boorjian.stephen@mayo.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Curtis Pettaway</last_name>
      <phone>713-792-3250</phone>
      <email>cpettawa@mdanderson.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Velindre NHS Trust</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 2TL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr James Barber</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Leicester NHS Trust</name>
      <address>
        <city>Leicester</city>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Christopher Kent</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>St George's Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mr Nick Watkin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Norfolk and Norwich University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Norwich</city>
        <zip>NR4 7UY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mr Vivekanandan Kumar</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Swansea Bay University Health Board</name>
      <address>
        <city>Swansea</city>
        <zip>SA6 6NL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.icr.ac.uk/our-research/our-research-centres/clinical-trials-and-statistics-unit/clinical-trials/inpact</url>
    <description>Related Info</description>
  </link>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>September 23, 2014</study_first_submitted>
  <study_first_submitted_qc>November 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2014</study_first_posted>
  <last_update_submitted>October 30, 2019</last_update_submitted>
  <last_update_submitted_qc>October 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Penis cancer</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Chemoradiotherapy</keyword>
  <keyword>Surgery</keyword>
  <keyword>Phase III</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

